Invention Grant
US09433607B2 Composition for prevention or treatment of cancer comprising N-methylenenaphtho[2,1-b]furan-2-carbohydrazide derivatives as an active ingredient
有权
用于预防或治疗癌症的组合物，其包含N-亚甲基萘并[2,1-b]呋喃-2-碳酰肼衍生物作为活性成分
![Composition for prevention or treatment of cancer comprising N-methylenenaphtho[2,1-b]furan-2-carbohydrazide derivatives as an active ingredient](/docs/US/2016-09-06/US09433607B2/abs.jpg.600x600.jpg)
- Patent Title: Composition for prevention or treatment of cancer comprising N-methylenenaphtho[2,1-b]furan-2-carbohydrazide derivatives as an active ingredient
- Patent Title (中): 用于预防或治疗癌症的组合物，其包含N-亚甲基萘并[2,1-b]呋喃-2-碳酰肼衍生物作为活性成分
-
Application No.: US14641065Application Date: 2015-03-06
-
Publication No.: US09433607B2Publication Date: 2016-09-06
- Inventor: Bo Yeon Kim , Krisada Sakchaisri , Sun Ok Kim , Ramegowda Thimmegowda Naraganahalli , Nak Kyun Soung , Jong Seog Ahn , Joonsung Hwang , In Ja Ryoo , Jae-Hyuk Jang
- Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
- Applicant Address: KR Daejeon
- Assignee: Korea Research Institute of Bioscience and Biotechnology
- Current Assignee: Korea Research Institute of Bioscience and Biotechnology
- Current Assignee Address: KR Daejeon
- Agency: Klarquist Sparkman, LLP
- Priority: KR10-2012-0099412 20120907; KR10-2013-0107289 20130906
- Main IPC: A61K31/40
- IPC: A61K31/40 ; A61K31/405 ; A61K31/34 ; A61K31/343 ; A61K31/4045
![Composition for prevention or treatment of cancer comprising N-methylenenaphtho[2,1-b]furan-2-carbohydrazide derivatives as an active ingredient](/abs-image/US/2016/09/06/US09433607B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to ethyl(2-methyl-3{(E)-[(naphtho[2,1-b]furan-2-ylcarbonyl)hydrazono]methyl}-1H-indole-1-yl)acetate, the novel mitosis inhibitor. The said ethyl(2-methyl-3{(E)-[(naphtho[2,1-b]furan-2-ylcarbonyl)hydrazono]methyl}-1H-indole-1-yl)acetate not only induces apoptosis by inhibiting tubulin polymerization in the course of mitosis but also displays an excellent anticancer effect in the multi-drug resistant cancer cells, so that it can be effectively used for the treatment of cell proliferative disease including various cancers.
Public/Granted literature
Information query
